glp-1 max for diabetes receptor agonists in the treatment of type 2 – state-of-the-art PURE HEALTH MAX Ultimate GLP-1
Description
Liraglutide 3.0 mg reduced BMI by 4.3% over 56 weeks in adolescents with obesity, while placebo reduced BMI by 0.3% in the long term [115]
Lancet 392, 15191529 (2018)
The supplement is tested by NSF, an independent testing organization, for safety and dosage claims
These terms are not intended to indicate clinical equivalence to prescription medications or guaranteed outcomes, and readers are encouraged to verify the full product details directly from the official source
This improves tolerability, as gastrointestinal effects are most severe at initiation and generally wane over time
